BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26684479)

  • 1. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM; Hershfield MS; Bahna SL
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
    Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
    Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS; Chaffee S; Sorensen RU
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
    Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
    Front Immunol; 2018; 9():113. PubMed ID: 29456531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.
    Moretti FA; Giardino G; Attenborough TCH; Gkazi AS; Margetts BK; la Marca G; Fairbanks L; Crompton T; Gaspar HB
    Sci Rep; 2021 Dec; 11(1):23221. PubMed ID: 34853379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.
    Kaufman DA; Hershfield MS; Bocchini JA; Moissidis IJ; Jeroudi M; Bahna SL
    Pediatrics; 2005 Dec; 116(6):e876-9. PubMed ID: 16263974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy.
    Grunebaum E; Reid B; Naqvi A; Hershfield MS; Kim VH; Muller MP; Hicks LK; Lee E; Betschel S; Roifman CM
    Clin Immunol; 2020 Feb; 211():108321. PubMed ID: 31812707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
    Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
    J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS
    Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract]   [Full Text] [Related]  

  • 14. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
    Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
    J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency.
    Grunebaum E; Cutz E; Roifman CM
    J Allergy Clin Immunol; 2012 Jun; 129(6):1588-93. PubMed ID: 22409989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
    Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
    J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of ADA-Deficient SCID Patient on Adagen During Pregnancy.
    Shams M; Kobrynski L
    J Clin Immunol; 2019 Nov; 39(8):846-848. PubMed ID: 31620946
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies.
    Grunebaum E; Cohen A; Roifman CM
    Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):630-8. PubMed ID: 24113229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.